Semaglutide belongs to a class of medications called GLP-1 receptor agonists, and when it is taken, it can activate certain receptors in the brain
Comparison of adverse reactions between semaglutide combined with metformin and metformin alone cohorts As shown in Figure 9, the results of adverse reactions, such as hypoglycemia, gastrointestinal reactions and dizziness and headache, between the two groups had no significant difference (SMD=1.58, 95% CI=[0.47, 5.25], P=0.736
The brain-semaglutide can cause a loss of appetite and weight loss
Time spent at elevated temperatures accelerates degradation
Semaglutide is a once-weekly injection that supports weight loss and helps regulate blood sugar
Results indicated that semaglutide not only aids in weight loss but also improves cardiometabolic risk factors